Sign in
Active, not recruitingNo phase

The Impact of Targeted Temperature Management Duration on Thrombin Function in Cardiac Arrest Patients

Key facts

Who runs it
Tang Ziren
Where
China1 site in 1 countryChoose a country to see its sites
Trial code
Status
Active, not recruiting
People taking part
64 people, planned
Started
1 Dec 2024
Ended
31 Dec 2025
Type of study
Interventional, 2 groupsOne group gets an existing treatment, for comparison.
Treatments tested
  • Target Temperature Management Treatment
Record updated
11 April 2025

Who can take part

Age
18 years to 80 years
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 13 criteriaShow less

Who can take part

  • age between 18 and 80 years
  • Glasgow Coma Scale score of less than 8 upon admission
  • patients resuscitated after out-of-hospital cardiac arrest; and (4) patient or their legal representative has signed the informed consent form

Who cannot take part

  • uncorrected persistent cardiogenic shock, defined as a systolic blood pressure below 90 mmHg despite treatment with fluid resuscitation, vasopressors, and inotropic agents
  • cardiac arrest caused by irreversible factors such as trauma or poisoning
  • cardiac arrest due to terminal conditions like advanced cancer
  • pre-existing cerebrovascular disease or CT-confirmed intracerebral hemorrhage upon admission
  • bradycardia or sick sinus syndrome following the return of spontaneous circulation
  • pre-existing coagulation disorders or severe bleeding tendencies
  • pregnant or breastfeeding women, or women of childbearing age with elevated serum hCG levels
  • pre-arrest Cerebral Performance Category (CPC) score between 3 and 5
  • presence of treatment limitations (such as refusal by the patient or legal representative to undergo advanced life support, including mechanical ventilation, chest compressions, or targeted temperature management)
  • determination by the principal investigator that the patient is unsuitable for the trial

Where is this trial?

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

This study will be a single-center, prospective, randomized controlled trial with an estimated sample size of 64 patients. Eligible patients will be randomly assigned in a 1:1 ratio to receive TTM for either 24 hours or 72 hours. The primary outcome measure will be the changes in thrombin function indices at various time points during TTM treatment in both groups. The secondary endpoints of the study include additional coagulation function indicators, the incidence of bleeding-related events between the two groups, the amount of blood products used, the incidence of thrombotic events, and the CPC scores at 28 days and 6 months for both groups.

The 2 groups in the trial

  • 24-hour treatmentSham treatment, for comparison

    Treatment: Target Temperature Management Treatment

  • 72-hour treatmentExisting treatment, for comparison

    Treatment: Target Temperature Management Treatment

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
The Impact of Targeted Temperature Management Duration on Thrombin Function in Cardiac Arrest Patients (ITTC Trial): A Single-Center, Prospective, Randomized Controlled Trial
Record updated
11 April 2025